Showing results (61-70 of 69) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 69 results.
European Urology|December 21, 2024
Pembrolizumab Retreatment in Patients with Advanced or Metastatic Urothelial Carcinoma Who Responded to First-course Pembrolizumab-based TherapyVadim S Koshkin, Pongwut Danchaivijitr, Woo Kyun Bae, et al.
Clinical Genitourinary Cancer|November 23, 2024
Outcomes by Retrospective Eligibility for Maintenance Therapy of Patients With Advanced Urothelial Carcinoma: Post Hoc Analysis of the Phase 3 KEYNOTE-361 TrialRonac Mamtani, Nobuaki Matsubara, Alvaro Montesa Pino, et al.
European Urology Oncology|May 3, 2026
Pembrolizumab Plus Lenvatinib in Participants with Docetaxel-pretreated Metastatic Castration-resistant Prostate Cancer: Results from KEYNOTE-365 Cohort EMarinela Augustin, Brigitte Laguerre, Capucine Baldini, et al.
European Urology Focus|August 12, 2025
Vibostolimab Coformulated with Pembrolizumab in Participants with Docetaxel-pretreated Metastatic Castration-resistant Prostate Cancer: KEYNOTE-365 Cohort GPeter C Fong, Mariusz Kwiatkowski, Alessandra Mosca, et al.
The Lancet. Oncology|May 29, 2021
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trialThomas Powles, Tibor Csőszi, Mustafa Özgüroğlu, et al.
European Urology|August 22, 2024
Impact of Prior Chemotherapy on Response to Second-line Pembrolizumab in Urothelial Cancer: Exploratory Analysis of the Phase 3 KEYNOTE-045 TrialRonald de Wit, David J Vaughn, Yves Fradet, et al.
The Lancet. Oncology|September 2, 2022
Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trialThomas Powles, Piotr Tomczak, Se Hoon Park, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 30, 2024
Association of Tumor Mutational Burden and PD-L1 with the Efficacy of Pembrolizumab with or without Chemotherapy versus Chemotherapy in Advanced Urothelial CarcinomaAude Fléchon, Rafael Morales-Barrera, Thomas Powles, et al.
The New England Journal of Medicine|August 18, 2021
Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell CarcinomaToni K Choueiri, Piotr Tomczak, Se Hoon Park, et al.
Pageof 7